Kidney Multiphoton Analysis of Therapeutic Agents

治疗药物的肾脏多光子分析

• 批准号: 7218512
• 负责人: KENNETH W DUNN
• 金额: $ 10万
• 依托单位: INPHOTON, LLC
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7218512
• 关键词: Adverse effects; Affect; Animal Disease Models; Animals; Biological Assay; Biological Products; Biophysics; Cells; Cellular Assay; Cellular biology; Complement; Development; Disease; Drug Delivery Systems; Drug Industry; Drug toxicity; Economics; Evaluation; Fluorescence Microscopy; Housing; Image; Image Analysis; Imaging Techniques; Imaging technology; Individual; Industry; Kidney; Knowledge; Life; Location; Marketing; Medicine; Metabolism; Microscopic; Microscopy; Multiphoton Fluorescence Microscopy; Operative Surgical Procedures; Organ; Other Imaging Modalities; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physiological; Physiology; Preclinical Drug Development; Preclinical Drug Evaluation; Procedures; Rattus; Renal function; Research Contracts; Resolution; Safety; Savings; Services; Standards of Weights and Measures; Techniques; Technology; Therapeutic Agents; Therapeutic Effect; Time; Translating; digital imaging; drug development; in vivo; insight; intravital microscopy; multi-photon; pre-clinical; response; trafficking; uptake

DESCRIPTION (provided by applicant): The integrated scientific team of INphoton, LLC will develop standard operating procedures for intravital multiphoton microscopy assays quantifying fluorescent drug delivery, cellular uptake, intracellular distribution, metabolism, and physiologic/therapeutic effects within the kidney of live rats. Refinement of some existing assays will be necessary for commercial utilization. The resulting products will enable INphoton to extend commercial services to pharmaceutical and biotech companies to enhance preclinical evaluation of potential products. INphoton, LLC will commercialize multiphoton microscopy for preclinical drug evaluation in the kidney. This will greatly aid evaluation of a potential therapeutic agent's cellular location, functional effects and adverse affects. Since this is not possible with other imaging modalities, this approach complements and extends existing imaging technologies.

描述（由申请人提供）：INphoton， LLC的综合科学团队将开发活体多光子显微镜分析的标准操作程序，定量荧光药物传递、细胞摄取、细胞内分布、代谢和活体大鼠肾脏内的生理/治疗效应。为了商业利用，需要改进一些现有的测定方法。由此产生的产品将使INphoton能够向制药和生物技术公司提供商业服务，以加强对潜在产品的临床前评估。INphoton， LLC将商业化用于肾脏临床前药物评估的多光子显微镜。这将极大地帮助评估潜在治疗剂的细胞定位、功能效应和不良影响。由于其他成像方式无法做到这一点，因此该方法是对现有成像技术的补充和扩展。